BACKGROUND: Immunosuppressive therapy (IST) with anti-T lymphocyte globulin (ATG) plus cyclosporine (CSA) is standard therapy in patients with non-severe aplastic anemia (AA) in need of treatment and severe aplastic anemia (SAA) who do not have an available HLA-matched donor. The aim of this study was to analyze patients submitted to different ATG preparations as first-line treatment. PATIENTS AND METHODS: We retrospectively analyzed adult aplastic anemia (AA) patients who received ATG as first-line treatment between 1999 and 2013 to compare hematologic response and survival. RESULTS: During the time period mentioned 4 different ATG preparations had been used in 38 AA patients (34 severe, 4 non-severe). Responses were better with Lymphoglobulin (6 complete response 1 partial response, 0 refractory disease and 2 death within 3 months after ATG, i.e. during induction), Thymoglobulin (3, 1, 4 and 1, respectively) or ATGAM (1, 2, 1 and 1) compared to the ATG-Fresenius (ATG-F) group (3, 0, 6 and 6) (P = .07). Statistically significant inferior results with ATG-Fresenius (3 complete or partial responses, 6 refractoriness and 6 induction deaths) were evident when other preparations are lumped together (14 complete or partial responses, 5 refractoriness and 4 induction mortalities) (P = .045). Estimated 1 year survival rates were 52.5% versus 76.9%, respectively (P = .13). CONCLUSIONS: These data support the notion that not all ATG preparations are suitable for use in AA.
BACKGROUND: Immunosuppressive therapy (IST) with anti-T lymphocyte globulin (ATG) plus cyclosporine (CSA) is standard therapy in patients with non-severe aplastic anemia (AA) in need of treatment and severe aplastic anemia (SAA) who do not have an available HLA-matched donor. The aim of this study was to analyze patients submitted to different ATG preparations as first-line treatment. PATIENTS AND METHODS: We retrospectively analyzed adult aplastic anemia (AA) patients who received ATG as first-line treatment between 1999 and 2013 to compare hematologic response and survival. RESULTS: During the time period mentioned 4 different ATG preparations had been used in 38 AA patients (34 severe, 4 non-severe). Responses were better with Lymphoglobulin (6 complete response 1 partial response, 0 refractory disease and 2 death within 3 months after ATG, i.e. during induction), Thymoglobulin (3, 1, 4 and 1, respectively) or ATGAM (1, 2, 1 and 1) compared to the ATG-Fresenius (ATG-F) group (3, 0, 6 and 6) (P = .07). Statistically significant inferior results with ATG-Fresenius (3 complete or partial responses, 6 refractoriness and 6 induction deaths) were evident when other preparations are lumped together (14 complete or partial responses, 5 refractoriness and 4 induction mortalities) (P = .045). Estimated 1 year survival rates were 52.5% versus 76.9%, respectively (P = .13). CONCLUSIONS: These data support the notion that not all ATG preparations are suitable for use in AA.
Authors: A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster Journal: Blood Date: 2000-03-15 Impact factor: 22.113
Authors: Manuel G Afable; Mohammed Shaik; Yuka Sugimoto; Paul Elson; Michael Clemente; Hideki Makishima; Mikkael A Sekeres; Alan Lichtin; Anjali Advani; Matt Kalaycio; Ramon V Tiu; Christine L O'Keefe; Jaroslaw P Maciejewski Journal: Haematologica Date: 2011-05-23 Impact factor: 9.941
Authors: Songul Serefhanoglu; Yahya Buyukasik; Tugrul Purnak; Hakan Goker; Nılgun Sayinalp; Ibrahim C Haznedaroglu; Osman I Ozcebe Journal: Med Princ Pract Date: 2011-05-11 Impact factor: 1.927
Authors: E Di Bona; F Rodeghiero; B Bruno; A Gabbas; P Foa; A Locasciulli; C Rosanelli; L Camba; P Saracco; A Lippi; A P Iori; F Porta; G De Rossi; B Comotti; P Iacopino; C Dufour; A Bacigalupo; V De Rossi Journal: Br J Haematol Date: 1999-11 Impact factor: 6.998
Authors: John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Carlos Vallejo; Pau Montesinos; Marta Polo; Beatriz Cuevas; Marta Morado; Ana Rosell; Blanca Xicoy; José L Díez; Olga Salamero; Ángel Cedillo; Pablo Martínez; Consolación Rayón Journal: Ann Hematol Date: 2015-02-13 Impact factor: 3.673